cv9103
Hormone Refractory Prostate Cancer
University of FloridavaccinePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Hormone Refractory Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Tianjin Medical University Cancer Institute and Hospital | Phase 3 | BB |
at-101 Ascenta Therapeutics | Phase 2 | BB |
RADIUM RA-223 Bayer | Phase 3 | BB |
Docetaxel Tianjin Medical University Cancer Institute and Hospital | Phase 3 | BB |
Denosumab Amgen | Phase 3 | B |
View all 43 →
Same molecule, other indications
cv9103 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →